The long-term effects of hyaluronic acid on hemiplegic shoulder pain and injury in stroke patients
A randomized controlled study

Yu-Chi Huang, MD*, Chau-Peng Leong, MD*, Hui-Hsin Tso, OT, Mei-Ju Chen, PT, Mei-Yun Liaw, MD, Han-Chin Hsieh, MD, Lin-Yi Wang, MD, Chia-Hao Hsu, MD

Abstract

Background: Hemiplegic shoulder pain (HSP) is one common complication after stroke. The interferes with the functionality of the affected shoulder in patients with stroke during rehabilitation. Hyaluronic acid (HA) could have positive effects on pain relief and shoulder motion in stroke patients with hemiplegic shoulders. We investigated long-term benefits of HA injection in stroke patients with HSP and rotator cuff injury.

Methods: A randomized, double-blinded controlled trial was conducted in one medical center. The stroke patients with HSP and rotator cuff injury were randomized and allocated to the control (n=9) and experimental (n=18) groups. The control and the experimental groups received ultrasound-guided subacromial 0.9% sodium chloride and HA injections, respectively. All injections were performed once per week for 3 weeks. The associated upper extremity functional assessments, shoulder pain scale, and sonography findings on affected shoulders were measured before interventions and at the 4th and 12th week after local injections.

Results: The visual analog scale (VAS) scores of HSP were significantly reduced in the control and experimental groups at the 4th week following intervention. Additionally, the VAS score at the 12th week was also significantly reduced in the experimental group. Significant differences were found in the hyperemia occurrence in the subscapularis tendon at the 12th week after intervention (P= .014) and in the severity of hyperemia in the long head of the biceps tendon (P= .042) and the subscapularis tendon after intervention (P= .014).

Conclusion: Subacromial HA injections might provide longer HSP reduction and decrease in hyperemia reactions at the long head of biceps tendon and subscapularis tendon in stroke patients with HSP and tendon injury.

Abbreviations: FMA-UE = Fugl-Meyer assessment for the upper extremity, HA = hyaluronic acid, HSP = hemiplegic shoulder pain, VAS = visual analog scale.

Keywords: hemiplegic shoulder pain, hyaluronic acid, sonography, stroke

1. Introduction

Hemiplegic shoulder pain (HSP) is a common comorbidity in stroke patients with hemiplegia. HSP impedes functional outcomes due to its negative effects on motor function of affected shoulders, daily activities, and length of hospital stay after stroke.[1-3] The pathogenesis of HSP is still not well determined and previous investigators proposed that impaired shoulder function, restricted shoulder motion, shoulder subluxation, shoulder spasticity, reflex sympathetic dystrophy, and rotator cuff injuries are contributors of HSP.[4-6] There are some other interventions available, including medications, local injections, rehabilitation, taping, and exercises, to treat HSP in patients with stroke.[7-15] Rotator cuff injury is considered to be one important factor related to HSP in patients with subacute stroke.[5,16] Clinically, the patients with shoulder pain may receive steroid or hyaluronic acid (HA) injections to alleviate pain associated with local inflammation.[9,12,17-19] The reduction of HSP after steroid injections was significantly effective, whereas the long-term adverse effects of steroid injections, including skin depigmentation, tissue degeneration, and tendon rupture, were also reported.[20] Since stroke patients with HSP were frequently associated with rotator cuff injury, we considered HA injection could be an alternative and safer intervention for HSP.

*Correspondence: Chau-Peng Leong and Yu-Chi Huang, Department of Physical Medicine and Rehabilitation, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan (e-mails: cpleong@adm.cgmh.org.tw, hyuchi@gmail.com).
pain and motion and activities of daily living.[26] Regarding patients with rotator cuff injury, some researchers found that subacromial HA injection resulted in positive effect on pain reduction lasting from 6 to 12 weeks.[18,27] According to our pilot study, we found that HA injection led to the short-term benefits on HSP and motor function recovery in stroke patients with HSP and rotator cuff injury.[28] There was no further study to explore the long-term effects of HA injection on HSP and shoulder injury in stroke patients with hemiplegia. The aim of this study was to investigate the long-term effects of HA injection for reducing pain and inflammation reactions of rotator cuff and biceps tendon at the 12th week of the study in subacute stroke patients with hemiplegic shoulder injury and pain.

2. Materials and methods

2.1. Study design

The study was a double-blinded, randomized controlled trial (clinical trial registration number NCT02464853). A parallel-group design with allocation concealment was used in this study. It was originally designed that the ratio of the enrolments in experimental group to control group was 2 to 1. Before the beginning of this trial, a serial number had been set up and was randomly categorized into either experimental group or control group by the research assistant. Therefore, the patients would be categorized into one of the group based on the number they picked. The participants and their caregivers would not receive any information related to the medicine they injected. Therapists who are responsible for assessing outcomes were not involving during the intervention process. After the trial commencement, there was no significant change being made. All the participants were enrolled between February 2015 and January 2017 at a rehabilitation unit of a single medical center in Taiwan.

2.2. Participants

Of the 127 stroke patients with HSP who admitted or those who visited the rehabilitation unit at a medical center, 27 stroke patients met the inclusive criteria and were recruited and completed all the procedures in this study (Fig. 1). The inclusion criteria are listed below: stroke patients with unilateral hemiplegia (stroke onset within 6 months), presence of HSP assessed by the visual analog scale (VAS), the shoulder pain scale score equal to or more than 3, and weakened shoulders with soft tissue injuries revealed by musculoskeletal sonography. The exclusion criteria were taking anticoagulation therapy, shoulder pain or soft tissue injury before stroke, other neuromuscular disease, or impaired communication that does not allow understanding or cooperating within the procedures. This clinical trial was approved by the Institutional Review Board at our hospital. All investigators followed the ethical principles for medical research according to the Declaration of Helsinki 2013. The patients understood the study protocol and procedures, and the written informed consent was obtained from each participant before trial execution.

2.3. Interventions

We randomly allocated the stroke patients into the control and experimental groups before interventions. A research assistant used sequentially numbered and sealed envelopes to perform randomization. In the control group, 9 patients received a 2.5 mL 0.9% sodium chloride injection into the subdeltoid bursa under ultrasound guidance. In the experimental group, 18 patients with stroke received a 2.5 mL sodium hyaluronate injection (ARTZ Dispo, Seikagaku, Tokyo, Japan) into the subdeltoid bursa under ultrasound guidance. Total 3 injections for each patient were performed (once a week for 3 weeks) and administered by 1 experienced physiatrist. The participants were blinded to the content of local injections in this study.

2.4. Outcome measures

A physical therapist, also blinded to the content of local injections, assessed the related parameters before, 4- and 12-week after treatment. These included shoulder spasticity, measured by the modified Ashworth scale[29,30], shoulder subluxation, examined by a finger breadth to evaluate the distance between the lateral border of the acromion and the proximal part of humeral head; pain-free range of motion of the hemiplegic shoulder, measured with a goniometer; Fugl-Meyer assessment for the upper extremity (FMA-UE)[31]; and the severity of HSP. The medications for pain control and rehabilitation sessions were recorded during the 12-week period in this study. The physical and occupational therapists were informed about injured shoulders in the participants and also had been instructed proper techniques during performing exercises. The presence of HSP was noted while resting or during passive shoulder motion, and the pain severity was assessed by a 10-cm VAS. All shoulder sonographic images were evaluated by the same experience physiatrist certificated by Taiwan Society of Ultrasound in Medicine. The physician performed a musculoskeletal sonography using a 9 to 14 MHz linear-array transducer (ACUSON S2000; Siemens, Malvern, PA). The long head of the biceps tendon, subscapularis tendon, supraspinatus, and infraspinatus tendons, and subdeltoid bursa were investigated in this study. Their echogenicity and the thickness of each tendon, the fluids surrounding tendons, or in the bursa, were evaluated and measured. We assessed inflammatory responses of these soft tissues in hemiplegic shoulders by color Doppler sonography, and recorded the hyperemia level according to the following grading: the color Doppler sonography signal was scored as grade 0 (no color flow signal), grade 1 (<5 color spots or a short line), grade 2 (5–6 color spots or short lines), or grade 3 (>6 color spots or color lines).[32] The physical assessments, shoulder pain, and shoulder sonography were evaluated at baseline, the 4th and 12th week after intervention for each participant. After the trial commencement, there were no significant changes about outcome measure being made.

2.5. Statistical analysis

Categorical variables between groups were compared using Fisher exact test, and continuous variables were compared by Mann–Whitney U test. Variables before and after intervention within group were compared by the Wilcoxon signed-rank test. Within-group comparisons of the structural findings and hyperemia level on shoulder sonography were analyzed by generalized linear models and the Friedman test, respectively. A P-value less than .05 was set as statistically significant. All statistical tests were performed using SPSS 19.0 (SPSS, Inc., Chicago, IL).

3. Results

The data was collected and analyzed in April 2017, when the participants completed the injections and following assessments
after intervention. There were no reports of harmful side effects after receiving subacromial HA or normal saline injections in this trial. Table 1 shows the clinical characteristics, including demography, shoulder spasticity, subluxation, upper extremity function, shoulder motion, and pain levels before intervention in the participants and presents the medication and rehabilitation conditions in this study. There were no significant differences in clinical variables between the control and experimental groups before intervention. In the study, no significant differences were found in medication and rehabilitation program between these 2 groups. In within-group comparisons, no significant differences were found in shoulder spasticity, subluxation, shoulder flexion, and abduction at the 4th and 12th week after intervention in both control and experimental groups (Table 2). There were significant differences in VAS and FMA-UE scores between baseline and the 4th week in the control group ($P=.015$ and $.041$, respectively; Table 2; Fig. 2). In the experimental group, there were significant differences in VAS and FMA-UE scores between baseline and the 4th week ($P=.001$ and $.009$, respectively), and in VAS scores between the 4th and 12th week after intervention ($P=.041$; Table 2; Fig. 2).

Comparisons of shoulder structural changes on hemiplegic shoulders between baseline and after intervention in the control and experimental groups are presented in Tables 3 and 4. There

Figure 1. Flow diagram of eligible patients selected for this study.
were no significant differences in the incidence of tendon tear, tenosynovitis, and bursitis at the long head of biceps tendon and rotator cuff, but significant differences were observed in the incidence of the hyperemia in the subscapularis tendons on shoulder sonography between the 4th and 12th week after intervention in the experimental group (P=0.018; Table 3). The levels of hyperemia at tendons were significantly different at the long head of the biceps tendon and the subscapularis tendon after intervention in the experimental group (P=0.042 and 0.014, respectively; Table 4).

4. Discussion

In this trial, subacromial HA injection was used to manage the HSP and injury in subacute stroke patients with hemiplegic shoulders. According to the findings of our previous pilot study, subacromial HA injection could provide some benefits on pain reduction and motor function improvement of hemiplegic shoulders. In this longitudinal study, the results supported that the HA injection could not only provide HSP reduction lasting for 12 weeks, but also decrease the prevalence of inflammatory reactions in the subscapularis tendon at the 12th week after intervention. Furthermore, we also found that the levels of inflammatory responses at the long head of the biceps tendon and the subscapularis tendon were progressively decreased in the following 12 weeks after HA injection. In a randomized control trial, Rah et al reported that subacromial corticosteroid injection could reduce HSP and improve shoulder motion which had been lasting for 8 weeks in chronic stroke patients.[33] The efficacy and duration for pain reduction by subacromial corticosteroid injection was similar to the benefits for pain relief by subacromial HA injection in subacute stroke patients presented in our study.

Stroke patients with flaccid shoulders have a high tendency to get an injury of the weakened shoulders while performing daily activities and rehabilitation. Steroids could provide effective pain reduction and motor function improvement of hemiplegic shoulders. In this trial, the results supported that the HA injection could not only provide HSP reduction lasting for 12 weeks, but also decrease the prevalence of inflammatory reactions in the subscapularis tendon at the 12th week after intervention. Furthermore, we also found that the levels of inflammatory responses at the long head of the biceps tendon and the subscapularis tendon were progressively decreased in the following 12 weeks after HA injection. In a randomized control trial, Rah et al reported that subacromial corticosteroid injection could reduce HSP and improve shoulder motion which had been lasting for 8 weeks in chronic stroke patients. The efficacy and duration for pain reduction by subacromial corticosteroid injection was similar to the benefits for pain relief by subacromial HA injection in subacute stroke patients presented in our study.
Figure 2. Comparing the VAS score from time to time within each group. The vertical axis represents VAS scores; the transverse axis represents the 3 scheduled times of the assessments. VAS = visual analog scale. *Represents significant improvement (*P < .05).

Table 3
Comparison of the structural findings on shoulder sonography in the control and experimental groups.

|                        | Control group (n = 9) | Experimental group (n = 18) |
|------------------------|-----------------------|----------------------------|
|                        | Baseline 4th wk 12th wk | P<sub>1</sub> P<sub>2</sub> | Baseline 4th wk 12th wk | P<sub>1</sub> P<sub>2</sub> |
| **Biceps tendon**      |                       |                            |                       |                            |
| Effusion, tenosynovitis, tendinitis, tear, n, % | 8 (88.9) 8 (88.9) 8 (88.9) | .999 .999 | 14 (77.8) 15 (83.3) 16 (88.9) | .306 .564 |
| Hyperemia, n, % | 9 (100) 7 (77.8) | .567 | 14 (77.8) 15 (83.3) 15 (72.2) | .308 .141 |
| **Subscapularis tendon** |                       |                            |                       |                            |
| Tendinitis, tear, n, % | 6 (66.7) 9 (100) 5 (55.6) | .654 | 14 (77.8) 13 (72.2) 14 (77.8) | .305 .561 |
| Hyperemia, n, % | 6 (66.7) 5 (56.6) 4 (44.4) | .560 .560 | 7 (38.9) 7 (38.9) 2 (11.1) | .999 .018* |
| **Supraspinatus tendon** |                       |                            |                       |                            |
| Tendinitis, tear, n, % | 9 (100) 9 (100) 8 (88.9) | . | 15 (83.3) 17 (94.4) 17 (94.4) | .158 .999 |
| Hyperemia, n, % | 7 (77.8) 5 (55.6) 5 (55.6) | .125 .999 | 11 (61.1) 14 (77.8) 10 (55.6) | .168 .151 |
| **Infraspinatus tendon** |                       |                            |                       |                            |
| Tendinitis, tear, n, % | 1 (11.1) 1 (11.1) 2 (22.2) | .999 .303 | 0 (0) 0 (0) 1 (5.6) | . |
| Hyperemia, n, % | 0 (0) 1 (11.1) 0 (0) | . | 0 (0) 0 (0) 0 (0) | . |
| **Subdeltoid bursitis** |                       |                            |                       |                            |
| Effusion, tenosynovitis, tendinitis, tear, n, % | 4 (44.4) 3 (33.3) 5 (55.6) | .293 .412 | 7 (38.9) 7 (38.9) 7 (38.9) | .999 .999 |

Generalized linear models. P<sub>1</sub>: comparisons of the results between baseline and the 4th wk; P<sub>2</sub>: comparisons of the results between the 4th wk and the 12th wk.

Table 4
Comparison of hyperemia levels on shoulder sonography in the control and experimental groups.

|                        | Control group (n = 9) | Experimental group (n = 18) |
|------------------------|-----------------------|----------------------------|
|                        | Baseline 4th wk 12th wk | P  | Baseline 4th wk 12th wk | P  |
| **Biceps, mean (SD)** | 1.78 (0.8) 1.56 (0.9) | .861 | 1.72 (0.8) 1.39 (0.9) | 1.17 (0.9) |
| **Subscapularis, mean (SD)** | 1.11 (1.1) 0.89 (1.2) | .554 | 0.61 (0.9) 0.50 (0.7) | 0.11 (0.3) |
| **Supraspinatus, mean (SD)** | 0.89 (0.6) 0.78 (0.8) | .472 | 1.06 (1.1) 1.08 (0.7) | 0.75 (0.8) |
| **Infraspinatus, mean (SD)** | 0.00 (0.0) 0.00 (0.0) | .368 | 0.00 (0.0) 0.00 (0.0) | 0.00 (0.0) |
| **Bursa, mean (SD)** | 1.22 (1.0) 1.00 (1.0) | .401 | 0.78 (0.9) 0.83 (0.8) | 0.61 (0.8) |

The Friedman test for within-group comparison hyperemia level in each tendon and bursa. P = comparisons of the results at 3 different time points.

*P < .05. SD = standard deviation.
rehabilitation. Besides, we also found a decline in pain score due to antiinflammatory effects. However, adverse effects after local injections of steroids were reported, including paler skin, tissue atrophy, tendon rupture, and even cartilage damage.\(^{(20,34-35)}\) HA may play an antiinflammatory role by inhibiting proinflammatory cytokines and cyclooxygenase-2/prostaglandin E2 production in rotator cuff injury.\(^{(18,37)}\) We considered HA could decrease inflammation leading to pain reduction, and HA did not do further harm at the soft tissues and bony structures of hemiplegic shoulders in stroke patients with high risk of rotator cuff injury. Therefore, we used subacromial HA injection instead of steroid injection to resolve inflammatory responses and to treat HSP in stroke patients with hemiplegic shoulder injury and pain.

This is the first longitudinal study to explore long-term effect of pain reduction and also to present its antiinflammatory responses on injured tendons by shoulder sonography in stroke patients with HSP and injury. There were significant reductions in hyperemia level surrounding or in the long head of the biceps tendon and the subscapularis tendon. Higher prevalence and inflammatory reactions of the supraspinatus tendon injury on hemiplegic shoulders did not change after injections. The explanation for this finding is that the supraspinatus tendon is at a higher risk of injury during activities and exercises because it is a key muscle involved in shoulder exercises and rehabilitation. Besides, we also found a decline in pain score of HSP during a 3-month period after HA injections. Subacromial HA injections could provide a longer antiinflammatory effect for stroke patients with injured tendons. It means that pain-reduction process continued during the following 3 months after interventions, which may be associated with decreased hyperemia at some of hemiplegic shoulder tendons due to HA local antiinflammatory effect.

The limitations in this study are listed below. First, we only recruited subacute stroke patients from 1 medical center and the total number of participants was limited. Second, the details and durations of performing various exercises program on injured shoulders, which may lead to further hemiplegic shoulder injury, were not exactly recorded. Furthermore, a 6-month period or longer follow-up was not assessed in stroke patients with HSP and injury. In future, more stroke patients with HSP and injury from multiple medical centers should be considered to evaluate clinical benefits of subacromial HA injections.

### 5. Conclusions

In summary, subacromial HA injections might provide a practical and effective therapy for stroke patients with shoulder injury and pain to relief HSP associated with decreased hyperemia reactions. We suppose that 3 subacromial HA local injections could offer some benefits for a longer period.

### Acknowledgment

The authors thank the coworkers in Chang Gung Memorial Hospital

### Author contributions

Conceptualization: Yu-Chi Huang, Chau-Peng Leong, Mei-Yun Liaw, Lin-Yi Wang.

Data curation: Hui-Hsin Tso, Mei-Ju Chen, Han-Chin Hsieh, Chia-Hao Hsu.

Formal analysis: Hui-Hsin Tso.

Investigation: Yu-Chi Huang.

Methodology: Yu-Chi Huang, Chau-Peng Leong, Mei-Ju Chen, Mei-Yun Liaw, Han-Chin Hsieh, Lin-Yi Wang.

Project administration: Yu-Chi Huang.

Supervision: Chau-Peng Leong.

Writing – original draft: Yu-Chi Huang.

Writing – review & editing: Yu-Chi Huang, Chau-Peng Leong, Mei-Yun Liaw, Lin-Yi Wang, Chia-Hao Hsu.

### References

1. Chae J, Mascarenhas D, Yu DT, et al. Poststroke shoulder pain: its relationship to motor impairment, activity limitation, and quality of life. Arch Phys Med Rehabil 2007;88:298–301.

2. Gilmore PE, Spaulding SJ, Vandervoort AA. Hemiplegic shoulder pain: implications for occupational therapy treatment. Can J Occup Ther 2004;71:36–46.

3. Lindgren I, Jonsson AC, Norrvang B, et al. Shoulder pain after stroke: a prospective population-based study. Stroke 2007;38:343–8.

4. Murie-Fernandez M, Carmona Iragui M, Gnanakumar V, et al. Painful hemiplegic shoulder in stroke patients: causes and management [in Spanish]. Neurologia 2012;22:24–44.

5. Turner-Stokes L, Jackson D. Shoulder pain after stroke: a review of the evidence base to inform the development of an integrated care pathway. Clin Rehabil 2002;16:276–98.

6. Aras MD, Gokkaya NK, Comert D, et al. Shoulder pain in hemiplegia: results from a national rehabilitation hospital in Turkey. Am J Phys Med Rehabil 2004;83:713–9.

7. Chae J, Yu DT, Walker ME, et al. Intramuscular electrical stimulation for hemiplegic shoulder pain: a 12-month follow-up of a multiple-center, randomized clinical trial. Am J Phys Med Rehabil 2005;84:832–42.

8. Chantaine A, Barbeault A, Ubelhart D, et al. Shoulder pain and dysfunction in hemiplegia: effects of functional electrical stimulation. Arch Phys Med Rehabil 1999;80:528–31.

9. Penning LI, de Bie RA, Wakenkamp GH. The effectiveness of injections of hyaluronic acid or corticosteroid in patients with subacromial impingement: a three-arm randomised controlled trial. J Bone Joint Surg Br 2012;94:1246–52.

10. Ada L, Foongchomcheay A. Efficacy of electrical stimulation in preventing or reducing subluxation of the shoulder after stroke: a meta-analysis. Aust J Physiother 2002;48:257–67.

11. Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 2008;39:126–31.

12. Lakse E, Gunduz B, Erhan B, et al. The effect of local injections in hemiplegic shoulder pain: a prospective, randomized, controlled study. Am J Phys Med Rehabil 2009;88:805–11. quiz 812–904, 851.

13. Koog YH, Jin SS, Yoon K, et al. Interventions for hemiplegic shoulder pain: systematic review of randomised controlled trials. Disabil Rehabil 2010;32:282–91.

14. Poduri KR. Shoulder pain in stroke patients and its effects on rehabilitation. J Stroke Cerebrovasc Dis 1993;3:261–6.

15. Huang YC, Leong CP, Wang L, et al. Effect of kinesiology taping on hemiplegic shoulder pain and functional outcomes in subacute stroke patients: a randomized controlled study. Eur J Phys Med Rehabil 2016;52:774–81.

16. Huang YC, Liang PJ, Pong YP, et al. Physical findings and sonography of hemiplegic shoulder in patients after acute stroke during rehabilitation. J Rehabil Med 2010;42:21–6.

17. Shibata Y, Murokikawa K, Emoto G, et al. Clinical evaluation of sodium hyaluronate for the treatment of patients with rotator cuff tear. J Shoulder Elbow Surg 2001;10:209–16.

18. Chou WY, Ko JY, Wang FS, et al. Effect of sodium hyaluronate treatment on rotator cuff lesions without complete tears: a randomized, double-blind, placebo-controlled study. J Shoulder Elbow Surg 2001;10:209–16.

19. Merolla G, Bianchi P, Porcellini G. Ultrasound-guided subacromial injections of sodium hyaluronate for the management of rotator cuff tendinopathy: a prospective comparative study with rehabilitation therapy. Musculoskelet Surg 2013;97(Suppl 1):49–56.

20. Halpern AA, Horowitz BG, Nagel DA. Tendon ruptures associated with corticosteroid therapy. West J Med 1977;127:378–82.
[21] Nganvongpanit K, Boonsri B, Sripratak T, et al. Effects of one-time and
two-time intra-articular injection of hyaluronic acid sodium salt after
joint surgery in dogs. J Vet Sci 2013;14:215–22.
[22] Punzi L. The complexity of the mechanisms of action of hyaluronan in
joint diseases. Clin Exp Rheumatol 2001;19:242–6.
[23] Levillain A, Magaritz E, Boulouger C, et al. Effects of a vissculosupple-
mentation therapy on rabbit menisci in an anterior cruciate ligament
transsection model of osteoarthritis. J Biomech 2017;58:147–54.
[24] Osti L, Berardocci M, di Giacomo V, et al. Hyaluronic acid increases
tendon derived cell viability and collagen type I expression in vitro:
comparative study of four different hyaluronic acid preparations by
molecular weight. BMC Musculoskelet Disord 2015;16:284.
[25] Fujioka-Kobayashi M, Muller HD, Mueller A, et al. In vitro effects of
hyaluronic acid on human periodontal ligament cells. BMC Oral Health
2017;17:44.
[26] Meloni F, Milia F, Cavazzuti M, et al. Clinical evaluation of sodium
hyaluronate in the treatment of patients with supraspinatus tendinosis
under echographic guide: experimental study of periartricular injections.
Eur J Radiol 2008;68:170–3.
[27] Moghtaderi A, Sajadiyeh S, Khorawi S, et al. Effect of subacromial
sodium hyaluronate injection on rotator cuff disease: a double-blind
placebo-controlled clinical trial. Adv Biomed Res 2013;2:89.
[28] Huang YC, Leong CP, Wang L, et al. The effects of hyaluronic acid on
hemiplegic shoulder injury and pain in patients with subacute stroke: a
randomized controlled pilot study. Medicine 2016;95:e5547.
[29] Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth
scale of muscle spasticity. Phys Ther 1987;67:206–7.
[30] Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis.
Practitioner 1964;192:540–2.
[31] Fugl-Meyer AR, Jaasko L, Leyman I, et al. The post-stroke hemiplegic
patient. 1. a method for evaluation of physical performance. Scand J
Rehabil Med 1975;7:13–31.
[32] Chiou HJ, Chou YH, Wu JJ, et al. Evaluation of calcific tendinitis of the
rotator cuff: role of color Doppler ultrasonography. J Ultrasound Med
2002;21:289–95. quiz 296–287.
[33] Rah UW, Yoon SH, Moon DJ, et al. Subacromial corticosteroid injection
on poststroke hemiplegic shoulder pain: a randomized, triple-blind,
placebo-controlled trial. Arch Phys Med Rehabil 2012;93:949–56.
[34] Cardone DA, Tallia AF. Joint and soft tissue injection. Am Fam Physician
2002;66:283–8.
[35] Honcharuk E, Monica J. Complications associated with intra-articular
and extra-articular corticosteroid injections. JBJS Rev 2016;4: pii:
01874474-201612000-00002.
[36] Pekarek B, Osher L, Buck S, et al. Intra-articular corticosteroid injections:
a critical literature review with up-to-date findings. Foot 2011;21:66–70.
[37] Mitsui Y, Gotoh M, Nakama K, et al. Hyaluronic acid inhibits mRNA
expression of proinflammatory cytokines and cyclooxygenase-2/prosta-
glandin E(2) production via CD44 in interleukin-1-stimulated sub-
acromial synovial fibroblasts from patients with rotator cuff disease.
J Orthop Res 2008;26:1032–7.